Intuitive Surgical, Inc. $ISRG Shares Bought by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,349 shares of the medical equipment provider’s stock after acquiring an additional 1,975 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $5,295,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Draper Asset Management LLC raised its stake in shares of Intuitive Surgical by 41.9% during the 4th quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock worth $2,848,000 after buying an additional 1,485 shares during the period. SteelPeak Wealth LLC raised its stake in shares of Intuitive Surgical by 28.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock worth $18,781,000 after buying an additional 9,364 shares during the period. Atlantic Union Bankshares Corp raised its stake in shares of Intuitive Surgical by 19.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock worth $10,179,000 after buying an additional 3,676 shares during the period. World Investment Advisors raised its stake in shares of Intuitive Surgical by 238.3% during the 3rd quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock worth $2,415,000 after buying an additional 3,803 shares during the period. Finally, E. Ohman J or Asset Management AB raised its stake in shares of Intuitive Surgical by 4.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 28,306 shares of the medical equipment provider’s stock worth $12,659,000 after buying an additional 1,123 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ISRG shares. Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price objective for the company in a research note on Wednesday, March 11th. UBS Group reduced their price objective on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Wall Street Zen downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Evercore reduced their price objective on Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating for the company in a research note on Monday, April 6th. Finally, Jefferies Financial Group reduced their price objective on Intuitive Surgical from $560.00 to $515.00 and set a “hold” rating for the company in a research note on Wednesday. Eighteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $581.91.

Intuitive Surgical Stock Down 1.0%

Shares of NASDAQ:ISRG opened at $478.82 on Friday. The business has a fifty day moving average of $477.54 and a two-hundred day moving average of $515.16. The stock has a market cap of $170.04 billion, a P/E ratio of 58.04, a PEG ratio of 3.78 and a beta of 1.68. Intuitive Surgical, Inc. has a 52-week low of $427.84 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.81 EPS. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.16 earnings per share for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Patricia L. Wadors sold 220 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $499.71, for a total value of $109,936.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 645 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $485.01, for a total value of $312,831.45. Following the completion of the sale, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. The trade was a 28.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 32,943 shares of company stock valued at $17,279,568 in the last quarter. Corporate insiders own 0.60% of the company’s stock.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q1 beat and bullish analyst notes reinforce the long‑term bull case — TipRanks highlights the quarter as building the bull case after ISRG topped expectations. TipRanks: ISRG Beats Q1 Expectations
• Positive Sentiment: Robert W. Baird raised its price target to $610, signaling confidence in upside after the quarter. Robert W. Baird Raises ISRG Price Target
• Positive Sentiment: BTIG reaffirmed a Buy rating, backing the view that execution and DV5 adoption support growth. BTIG Reaffirms Buy
• Neutral Sentiment: Analysis pieces note a shift to innovation‑led, value‑based revenue (da Vinci 5 pricing power and recurring sales) — this supports higher margin durability but is a multi‑quarter theme rather than an immediate catalyst. Yahoo: Innovation‑Led Growth Driving ISRG
• Neutral Sentiment: Company disclosed a contained cyber incident with remediation underway — a risk to monitor but described by management as contained during the earnings call. Yahoo: Growth, AI and Cybersecurity
• Positive Sentiment: Goldman Sachs raised its target and reiterated bullish upside, reflecting confidence in ISRG’s multi‑year growth runway. Goldman Sachs Forecasts Strong Price Appreciation
• Negative Sentiment: Jefferies cut its target to $515 and moved to Hold, trimming near‑term upside expectations — a contributor to downside pressure for traders focused on valuation. Jefferies Lowers ISRG Price Target
• Negative Sentiment: Leerink and several other firms trimmed targets (e.g., Leerink to $573), reflecting more conservative near‑term multiples despite the beat. Leerink Lowers ISRG Price Target
• Negative Sentiment: Raymond James issued a more pessimistic near‑term forecast, adding to mixed sell‑side guidance that can keep the stock range‑bound despite strong fundamentals. Raymond James Issues Pessimistic Forecast

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.